SVB Leerink analyst Richard Newitter upgrades Intersect ENT (NASDAQ:XENT) from Market Perform to Outperform and raises the price target from $21 to $23.
SVB Leerink Upgrades Intersect ENT to Outperform, Raises Price Target to $23
SVB Leerink analyst Richard Newitter upgrades Intersect ENT (NASDAQ:XENT) from Market Perform to Outperform and raises the price target from $21 to $23.
Related Posts
Traders Circulate Twitter Post ‘Users Are Reporting Problems With OpenAI / ChatGPT’
https://twitter.com/isdownapp/status/1636067210635497473
https://isdown.app/integrations/openai?c=1678903785
EXCLUSIVE: Longeveron Reports Cooperative Research, Development Deal With US Dept. Of Veterans Affairs For Addition Of A Miami Veterans Affairs Clinical Site To Its Ongoing Phase 2 Alzheimer’s Trial
Miami, Florida – April 13, 2022 - Longeveron Inc. (NASDAQ:LGVN)
("Longeveron" or "Company"), a clinical stage biotechnology company developing
cellular therapies for chronic, aging-related
Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $250
Barclays analyst Carter Gould maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $227 to $250.